Bioceres Crop Solutions Statistics
Total Valuation
BIOX has a market cap or net worth of $404.74 million. The enterprise value is $671.40 million.
Important Dates
The last earnings date was Monday, November 11, 2024, after market close.
| Earnings Date | Nov 11, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
BIOX has 62.85 million shares outstanding. The number of shares has increased by 0.07% in one year.
| Current Share Class | 62.85M |
| Shares Outstanding | 62.85M |
| Shares Change (YoY) | +0.07% |
| Shares Change (QoQ) | -1.41% |
| Owned by Insiders (%) | 1.42% |
| Owned by Institutions (%) | 11.63% |
| Float | 27.69M |
Valuation Ratios
The trailing PE ratio is 167.87 and the forward PE ratio is 16.43. BIOX's PEG ratio is 1.37.
| PE Ratio | 167.87 |
| Forward PE | 16.43 |
| PS Ratio | 0.92 |
| Forward PS | 0.92 |
| PB Ratio | 1.31 |
| P/TBV Ratio | 19.58 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | 1.37 |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | 274.79 |
| EV / Sales | 1.52 |
| EV / EBITDA | 11.42 |
| EV / EBIT | 16.43 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.27, with a Debt / Equity ratio of 0.77.
| Current Ratio | 1.27 |
| Quick Ratio | 0.87 |
| Debt / Equity | 0.77 |
| Debt / EBITDA | 4.29 |
| Debt / FCF | n/a |
| Interest Coverage | 1.55 |
Financial Efficiency
Return on equity (ROE) is 1.11% and return on invested capital (ROIC) is 4.31%.
| Return on Equity (ROE) | 1.11% |
| Return on Assets (ROA) | 3.10% |
| Return on Capital (ROIC) | 4.31% |
| Revenue Per Employee | $1.13M |
| Profits Per Employee | $6,281 |
| Employee Count | 389 |
| Asset Turnover | 0.54 |
| Inventory Turnover | 2.05 |
Taxes
In the past 12 months, BIOX has paid $2.18 million in taxes.
| Income Tax | 2.18M |
| Effective Tax Rate | 36.71% |
Stock Price Statistics
The stock price has decreased by -44.97% in the last 52 weeks. The beta is 0.47, so BIOX's price volatility has been lower than the market average.
| Beta (5Y) | 0.47 |
| 52-Week Price Change | -44.97% |
| 50-Day Moving Average | 7.33 |
| 200-Day Moving Average | 10.55 |
| Relative Strength Index (RSI) | 41.34 |
| Average Volume (20 Days) | 198,297 |
Short Selling Information
| Short Interest | 752,550 |
| Short Previous Month | 623,597 |
| Short % of Shares Out | 1.20% |
| Short % of Float | 2.72% |
| Short Ratio (days to cover) | 4.58 |
Income Statement
In the last 12 months, BIOX had revenue of $441.23 million and earned $2.44 million in profits. Earnings per share was $0.04.
| Revenue | 441.23M |
| Gross Profit | 176.09M |
| Operating Income | 40.87M |
| Pretax Income | 9.30M |
| Net Income | 2.44M |
| EBITDA | 58.77M |
| EBIT | 40.87M |
| Earnings Per Share (EPS) | $0.04 |
Full Income StatementBalance Sheet
The company has $38.20 million in cash and $267.00 million in debt, giving a net cash position of -$228.80 million or -$3.64 per share.
| Cash & Cash Equivalents | 38.20M |
| Total Debt | 267.00M |
| Net Cash | -228.80M |
| Net Cash Per Share | -$3.64 |
| Equity (Book Value) | 346.00M |
| Book Value Per Share | 4.92 |
| Working Capital | 80.50M |
Full Balance SheetCash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Full Cash Flow StatementMargins
Gross margin is 39.91%, with operating and profit margins of 9.26% and 0.55%.
| Gross Margin | 39.91% |
| Operating Margin | 9.26% |
| Pretax Margin | 1.35% |
| Profit Margin | 0.55% |
| EBITDA Margin | 13.32% |
| EBIT Margin | 9.26% |
| FCF Margin | -2.67% |